
Busy Amgen swings another deal, this time with RNA drugging player Arrakis for 'several billion'
Less than a week after inking a $1.9 billion collaboration with Flagship’s Generate to boost its AI capabilities, Amgen is returning to the dealmaking table.
The biopharma’s newest partner is Arrakis, as the companies announced Tuesday morning they will team up to develop five RNA degrader therapeutics, with Amgen retaining an option for more. Amgen will shell out $75 million upfront and promise “several billion dollars” in biobucks if all milestones are met, though the company wouldn’t pin an exact number.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.